MA-ANTERRA-CAPITAL
29.6.2021 14:02:13 CEST | Business Wire | Press release
Anterra Capital (“Anterra”), the international food and agriculture specialist venture capital firm, today announced the initial closing of its second food and agriculture technology fund, Anterra F&A Ventures II, raising $175 million, exceeding the targeted size of the fund. Due to the positive market reception for the fund’s mission and strategy, Anterra is tracking towards an upsized second fund, and anticipates a final closing in the third quarter, 2021.
Anterra’s unique investment approach has attracted commitments from a prestigious and aligned group of long-term oriented global investors, with continued support from Eight Roads Ventures, backed by Fidelity, and Rabo Investments, the captive investment arm of the largest global food and agricultural bank out of the Netherlands - Rabobank. New investors include Novo Holdings, a leading global life sciences investor based out of Denmark; Tattarang, one of Australia’s largest private investment groups and the holding company of the Forrest family’s private business interests; as well as other well-respected family offices, sovereign wealth funds, and state-owned investors that provide a global presence, spanning across multiple continents.
Anterra’s mission is to invest in and partner with entrepreneurs transforming our vital food economy through biotech and digital innovation across crop science, animal health, and human nutrition. As a research driven, value-focused specialist investor Anterra uniquely combines a traditional venture investment approach and “venture creation,” building and scaling transformative businesses with its deep industry knowledge and vast global network as a pioneer in the space. While investor interest is growing in the Food & Ag industry, early-stage investment in this essential segment significantly trails that of other key industries, for comparison, less than half of that in Pharma & Biotech (~$40 billion) and about a fifth of venture investment in Software (~$100 billion).
“The food economy is in critical condition, and new digital and biotech solutions are desperately needed in order to support better outcomes for farmers, consumers and the environment,” said Adam Anders, Managing Partner of Anterra Capital. “With the first close, we continue our mission to sustainably transform our food economy, building on our leadership position as an early-stage investor in markets such as plant and animal health, while actively expanding our investment activity across the food and agriculture value chain.”
Daniel Auerbach, Senior Managing Partner and Global Head of Eight Roads Ventures, one of Anterra’s original lead investors, added: “Within Food & Ag, Anterra sits at the intersection of life sciences and digital technology and our expanded investment reflects our confidence in Anterra’s mission, leadership and performance for us over the past eight years.”
“We are excited to partner with Anterra and support the fund’s transformational mission, which is aligned with our investment activity across the biotech space overall, and emphasizes our commitment to investing in innovation within Food & Agriculture,” said Kartik Dharmadhikari, a Partner of Novo Growth within Novo Holdings.
About Anterra
With offices in Amsterdam and Boston, Anterra Capital is an international specialist venture capital investor dedicated to financing the growth of technology-driven companies with incredible potential in food, agriculture, and animal health. Supported by multinational institutional investors, Anterra provides patient strategic capital to entrepreneurs and innovative companies sustainably transforming our global food system. Further information: www.anterracapital.com
About Eight Roads Ventures
Eight Roads Ventures is a global investment firm backed by Fidelity. Eight Roads Ventures manages $7bn of assets across its offices in China, Hong Kong, India, Japan, UK and the US. Our 50-year history of investing includes partnerships with over 300 companies such as Alibaba, AppsFlyer, BlackDuck, Chewy, Devoted Health, Flywire, Icertis, iPipeline, Kensho, Letgo, Made.com, Neo4j, Nuance, Paidy, Ping Identity, Pony.ai, PharmEasy, Shadowfax, Toast, Wallapop, WuXi PharmaTech, and Xoom. Further information: https://eightroads.com
About Novo Holdings A/S
Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further information: http://www.novoholdings.dk
About Rabo Investments
Rabo Investments is Rabobank’s PE investment franchise. It has invested over €1.5 billion worldwide within the cutting-edge Food & Agri, Sustainability, and Healthcare sectors in the Netherlands and within the Food & Agri sector worldwide. The investments range from growth capital for innovative start-ups and scale-ups to investments in established companies and funds. Further information: https://raboinvestments.com
About Tattarang
Tattarang is one of Australia’s largest private investment groups and is owned by the Forrest family. Its diverse investment portfolio spans across agri-food, energy, resources, property and lifestyle. The group is made up of six business divisions including Harvest Road which is one of Australia’s largest and most diverse agricultural businesses with an expanding portfolio of high-quality foods. Further information: www.tattarang.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005357/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FuzeBox AI Named Founding Co-Author of SPUR Coalition Technical Committee on Verifying AI Content Use5.10.2026 15:00:00 CEST | Press release
A new technical committee will define how publishers can independently confirm AI companies' reports of content use. FuzeBox AI has been named by the SPUR Coalition, an international nonprofit of 37 news and media organizations, as one of four founding co-authors of its Evidence Profile Technical Committee, adopted Sept. 2, 2026, to draft an evidence profile for SPUR's Content Telemetry standard: a way for publishers to verify AI usage reports without depending on the reporting company's cooperation. Under SPUR's current standard, AI companies self-report their content use. A company that skips reporting leaves no record, and publishers can't check what they do receive. On July 10, 2026, FuzeBox proposed its Verified Provenance Telemetry Standard (VPTS): publishers seed content with detectable markers, then verify their appearance in AI outputs via an auditable ledger, with no change to SPUR's standard. Within 48 hours, three organizations filed related proposals: ProRata on usage magn
Mary Kay Introduces the K-Beauty Texture Edit5.10.2026 14:02:00 CEST | Press release
Special-Edition Korea-Made Skin Care Collection Launches In 40 Markets, Available While Supplies Last Mary Kay Inc.,the iconic beauty giant announced today the launch of the K-Beauty Texture Edit, aspecial-edition skin care collection available while supplies last. The collection builds on the momentum of the company's largest consumer-facing global brand platform, Beauty Is More Beautiful Shared™ which launched in September. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005600130/en/ Mary Kay's Special Edition K-Beauty Texture Edit is a trend-forward collection which includes three Korea-made products: the Mary Kay® Melt-In Cleansing Balm, Mary Kay® Snail Gel Face Patches and Mary Kay® Collagen Moisturizing Gel. (Image Credit: Mary Kay Inc.) Inspired by Korea's globally influential skin care and self-care philosophy designed to bring playful textures, innovative ingredients, and elevated beauty experiences, the K-Beauty
GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.5.10.2026 14:00:00 CEST | Press release
Broadens GE HealthCare's footprint in the U.S. radiopharmaceutical industry, drives patient access to F18 labeled Positron Emission Tomography (PET) radiopharmaceuticals and enhances exposure to new high-growth areas Pharmaceutical Diagnostics (PDx) continues to partner with other established Contract Manufacturing Organizations (CMOs) to drive and expand patient access to its radiopharmaceutical portfolio, while SOFIE Biosciences continues to supply PET products from other leading radiopharmaceutical providers Provides U.S. rights to FAPI-74, a Phase III pipeline PET radiotracer with pan-cancer imaging potential, aiming to be among the first-to-launch in a large and fast-growing market1 GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subje
Henkell Freixenet Strengthens Premium Dealcoholized Sparkling Wine Production with Solos' Patented Aroma Recovery System5.10.2026 13:24:00 CEST | Press release
The installation marks a significant step in the evolution of premium No/Low wines, where preserving aroma and sensory quality has become a defining industry priority. Henkell Freixenet is expanding its premium dealcoholized sparkling wine production capabilities through the deployment of Solos Technology's patented Aroma Recovery System (ARS) at its Wiesbaden production site, the Group’s expertise centre for alcohol-free production. The installation represents a significant investment in next-generation dealcoholized sparkling wine production, helping preserve the natural aroma and sensory identity of the original wines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005959301/en/ Fürst von Metternich Riesling Alcohol-free on the bottling line, one of the first products in Henkell Freixenet’s portfolio developed in collaboration with Solos Technology. The project combines Henkell Freixenet's longstanding winemaking exper
Croma-Pharma Expands Its Portfolio in Canada With saypha® lips Lidocaine and Exprecell™5.10.2026 13:12:00 CEST | Press release
Croma-Pharma continues to build its portfolio in Canada, adding saypha® lips Lidocaine, a hyaluronic acid filler for lip augmentation,1 and Exprecell™, a medical device for the preparation of autologous PRP | Fluid-PRF.2 Both are distributed by Renellence, Croma's partner in Canada since 2025. The two additions reflect Croma's broader approach: pairing established hyaluronic acid expertise with autologous, regenerative technologies. Together, they give practitioners options across both aesthetic and regenerative treatment categories, from a single trusted source. "With saypha® lips Lidocaine and Exprecell™, we're giving Canadian practitioners a wider set of tools for facial aesthetics and regenerative treatments, each held to the same standard of precision and safety," said Andreas Prinz, Chief Executive Officer of Croma-Pharma GmbH. Renellence has distributed Croma's Saypha® hyaluronic acid filler range in Canada since October 2025, alongside medical education and training for Canadia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom